- December 14, 2022
To Date, Four Patients Are Now Cancer Free Out of 23 Evaluable
- November 7, 2022
Overall Response Rate 30.4 Percent in 23 Evaluable Patients Including Two Complete Responses and a Third Cancer-Free Patient
- October 13, 2022
Encouraging Safety and Efficacy Data from Ongoing GT-30 Study in Second-Line HCC
- October 12, 2022
Company Bolsters Management Team in Advance of Phase 2 Data Announcement and Preparations for Potential Registrational Clinical Trial
- March 24, 2022
Geneos expands its Phase Ib/IIa clinical trial in lead indication for treating patients with advanced hepatocellular carcinoma
- June 3, 2021
Geneos Therapeutics announced positive preliminary results of its ongoing first-in-human trial.
- March 16, 2021
Texas-based GMP Plasmid CDMO VGXI, Inc. and Geneos Therapeutics, Inc. Expand their Clinical Manufacturing Supply Agreement in Support of Geneos’ Ongoing GT-30 Phase Ib/IIa Clinical Trial for advanced hepatocellular carcinoma (HCC)
- March 3, 2021
Geneos Therapeutics has closed its Series A1 round, raising $12 million in financing.
- May 19, 2020
VGXI, Inc., Geneos Therapeutics’ CDMO partner, completes manufacturing of first GMP Lot under Clinical Manufacturing Supply Agreement.
- January 29, 2020
Geneos Therapeutics announced that its personalized neoantigen-targeting vaccine, GNOS-PV02 (based on its proprietary GT-EPIC™ platform), will be evaluated in a clinical trial for patients with advanced Hepatocellular Carcinoma (HCC).
- July 22, 2019
VGXI and Geneos Therapeutics have entered into a long-term master supply agreement to establish small-scale and rapid turnaround production services ideally suited for the personalized therapy approach.